Chugai Pharmaceutical Co., Ltd. (CHGCY)
Chugai Pharmaceutical Co., Ltd. operates in the Drug Manufacturers - General industry of the Healthcare sector, headquartered in Tokyo, SH, JP. The stock last traded at $22.26, down 0.89% on the session, giving a market capitalisation of $73.26B. On trailing twelve-month figures it carries a trailing P/E of 23.23, a net margin of 35.6%. Its beta of 0.56 implies it has historically moved less than the broad market.
Chugai Pharmaceutical Co., Ltd. is a prominent global pharmaceutical company, operating subsidiaries involved in the full lifecycle of drug development, from research and manufacturing to sales, import, and export, serving both Japanese and international markets. Its commercialized product portfolio spans several key therapeutic areas. These include a robust oncology offering with leading treatments like Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda. Additionally, it provides medications for bone health (e.g., Actemra, Edirol, Bonviva), renal conditions (such as Mircera and Oxarol), and neurological or other diverse ailments (including Hemlibra, CellCept, and Enspryng). Beyond its existing offerings, the company maintains an active research and development pipeline. This pipeline features multiple promising candidates targeting oncology, orthopedic and joint disorders, autoimmune diseases, kidney-related conditions, and various neurological or other health issues. Strategic partnerships are central to Chugai's operations, most notably a significant alliance with the Roche Group. The company also fosters collaborative research initiatives with academic institutions. Established in 1925, Chugai's headquarters are located in Tokyo, Japan, and it operates as a key subsidiary of Roche Holding Ltd.
Chugai Pharmaceutical Co., Ltd. is most often compared with the following Healthcare names: